Innatrix

Overview
Biopesticides?
Product stageSegments
Go-to-Market
?
Biochemical Pesticides
?

Innatrix is a biotechnology startup based in Research Triangle Park, North Carolina, focused on developing environmentally friendly biopesticides to combat crop diseases and pests. The company utilizes peptides to block disease-promoting proteins and RNA interference (RNAi) technology to deactivate genes essential for the survival of pests in crops. This approach offers new biological solutions as an alternative to traditional chemical-based pesticides, which are often overused and can cause environmental damage.

Innatrix's core product pipeline includes InnalB to prevent potato late blight, InnaNema to combat soybean cyst nematode, and InnaHLB to address citrus greening. These three products target infestations that collectively represent a combined US market worth approximately USD 800 million annually as of 2023. The company's peptide platform uses machine learning and artificial intelligence tools to identify promising molecular targets and generate leads to disrupt their function, targeting the virulence factors necessary for pathogens to cause crop diseases.

In 2023, Innatrix made significant progress in advancing its technology. Field trials for InnalB, the company's biopesticide candidate for potato late blight, are underway in North Carolina and Wisconsin, with data expected as early as September 2023. The goal is to have InnalB ready for market by 2026. Innatrix plans to eventually sell its biological products to agricultural chemical companies or pesticide distributors for distribution to farmers.

The company's biopesticides offer several advantages over conventional chemical treatments, including improved safety and environmental profiles, faster regulatory approval processes, and lower development costs. Biopesticides also play a crucial role in managing disease resistance to chemical pesticides by targeting new molecular targets and can be used effectively in tandem with conventional treatments.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
104 T.W. Alexander Drive Building 20 Building 20, Suite 2020 Durham NC USA
Founded year:
2013
Employees:
1-10
IPO status:
Private
Total funding:
USD 573.1 k
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.